Latest Ratios: P/E Ratio 73.7x · EV/EBITDA 53.5x · ROE 11.7%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.2B | $3.3B | $1.4B | $1.3B | $1.1B | $807M | $1.1B | $598M | $830M | — | — |
| Enterprise Value | $7.1B | $3.1B | $1.2B | $1.2B | $938M | $691M | $986M | $554M | $523M | — | — |
| P/E Ratio → | 73.67 | 55.00 | — | 87.70 | 5.76 | — | — | — | — | — | — |
| P/S Ratio | 7.66 | 4.81 | 3.34 | 4.67 | 4.79 | 20.94 | — | — | — | — | — |
| P/B Ratio | 13.23 | 5.74 | 3.22 | 2.87 | 2.66 | 4.36 | 3.50 | 2.65 | — | — | — |
| P/FCF | 36.73 | 128.20 | 55.59 | 95.78 | 185.01 | — | — | — | — | — | — |
| P/OCF | 281.96 | 126.82 | 55.00 | 94.84 | 181.66 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.58 | 2.93 | 4.31 | 4.26 | 17.92 | — | — | — | — | — |
| EV / EBITDA | 53.54 | 39.38 | — | — | 77.05 | — | — | — | — | — | — |
| EV / EBIT | 91.78 | 34.90 | — | — | 85.08 | — | — | — | — | — | — |
| EV / FCF | — | 122.06 | 48.76 | 88.52 | 164.52 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.6% | 54.6% | 85.6% | 79.1% | 89.6% | 76.4% | — | — | — | — | — |
| Operating Margin | 11.4% | 11.4% | -10.8% | -9.3% | 4.4% | -406.4% | — | — | — | — | — |
| Net Profit Margin | 8.7% | 8.7% | -10.2% | 5.2% | 83.3% | -409.7% | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.7% | 11.7% | -9.8% | 3.4% | 63.1% | -63.6% | -60.1% | -1037.7% | — | — | — |
| ROA | 8.8% | 8.8% | -7.8% | 2.9% | 53.0% | -54.2% | -53.4% | -56.2% | -55.9% | -124.8% | -42.5% |
| ROIC | 17.1% | 17.1% | -11.3% | -6.1% | 4.2% | -85.9% | -61.1% | -70.4% | — | — | — |
| ROCE | 14.0% | 14.0% | -9.7% | -5.8% | 3.3% | -62.0% | -57.8% | -67.2% | -69.9% | -155.3% | -44.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.03 | 0.01 | 0.03 | 0.02 | 0.01 | — | — | — |
| Debt / EBITDA | 0.12 | 0.12 | — | — | 0.49 | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.28 | -0.40 | -0.22 | -0.29 | -0.63 | -0.34 | -0.20 | — | — | — |
| Net Debt / EBITDA | -1.98 | -1.98 | — | — | -9.59 | — | — | — | — | — | — |
| Debt / FCF | — | -6.14 | -6.84 | -7.27 | -20.48 | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($166M) exceeds total debt ($9M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.79 | 3.79 | 3.30 | 4.34 | 5.16 | 4.38 | 10.46 | 8.68 | 7.37 | 2.70 | 24.47 |
| Quick Ratio | 3.39 | 3.39 | 3.04 | 3.85 | 4.71 | 4.30 | 10.46 | 8.68 | 7.37 | 2.70 | 24.47 |
| Cash Ratio | 2.98 | 2.98 | 2.42 | 3.24 | 4.05 | 4.06 | 10.16 | 8.39 | 7.22 | 2.61 | 24.31 |
| Asset Turnover | — | 0.89 | 0.73 | 0.51 | 0.48 | 0.17 | — | — | — | — | — |
| Inventory Turnover | 5.60 | 5.60 | 2.31 | 1.82 | 1.06 | 2.48 | — | — | — | — | — |
| Days Sales Outstanding | — | 8.40 | 35.98 | 28.72 | 33.68 | 37.74 | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.4% | 1.8% | — | 1.1% | 17.4% | — | — | — | — | — | — |
| FCF Yield | 2.7% | 0.8% | 1.8% | 1.0% | 0.5% | — | — | — | — | — | — |
| Buyback Yield | 0.1% | 0.2% | 0.4% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.1% | 0.2% | 0.4% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $79M | $71M | $72M | $70M | $69M | $62M | $54M | $30M | $32M | $32M |
Includes 30+ ratios · 10 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KNSA stock.
Kiniksa Pharmaceuticals International, plc's current P/E ratio is 73.7x. The historical average is 49.5x. This places it at the 67th percentile of its historical range.
Kiniksa Pharmaceuticals International, plc's current EV/EBITDA is 53.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 58.2x.
Kiniksa Pharmaceuticals International, plc's return on equity (ROE) is 11.7%. The historical average is -9.2%.
Based on historical data, Kiniksa Pharmaceuticals International, plc is trading at a P/E of 73.7x. This is at the 67th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Kiniksa Pharmaceuticals International, plc has 54.6% gross margin and 11.4% operating margin. Operating margin between 10-20% is typical for established companies.
Kiniksa Pharmaceuticals International, plc's Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Single-product dependency and margin ceiling
Metrics are mathematically derived from official filings.
Structural Margin Ceiling Offsets Operating Leverage
Kiniksa's operating margin expanded from -0.1% in 2024Q2 to 19.0% in 2026Q3, yet gross margin has settled near 53-55%, well below the 80-90% typical of asset-owning orphan drug companies, as reported in Kiniksa's quarterly filings, reflecting the Regeneron profit-share drag.
The decomposition is revealing: profitability improvement is coming almost entirely from operating leverage on SG&A rather than gross margin expansion, meaning each incremental ARCALYST dollar converts at a structurally lower rate than at peers who own their assets outright. Net margin of 16.6% in 2026Q3 sits below the 19.0% operating margin, suggesting below-the-line items — potentially collaboration expense allocation or tax normalization — are trimming the final conversion. For an analyst, the truest read of earning power is likely the operating margin, since net margin is further distorted by accelerating stock-based compensation (approximately 4.6% of revenue per the income statement analysis) and prior-year loss base effects.
Returns Recovering But Remain Capital-Shallow
ROIC swung from -4.7% in 2024Q4 to 7.2% in 2026Q3, per recent SEC filings, but this recovery is driven primarily by margin expansion rather than capital efficiency, with asset turnover improving only modestly from 0.20 to 0.30 over the same ten-quarter window.
A ROIC of 7.2% against a 3.91x current ratio implies that a large portion of Kiniksa's capital base is idle cash rather than revenue-generating invested capital, so the economic return on genuinely deployed assets is likely higher than the headline figure suggests. Conversely, the return profile is not yet compounding in a way that would justify premium pricing on a standalone basis; compared to the pre-2025 loss-making era, the improvement is real, but against historical pharma ROIC norms it remains modest. Investors should monitor whether KPL-404 commercialization can raise asset turnover structurally or whether the company remains a low-asset-intensity, cash-accumulating entity whose ROIC is diluted by its own balance sheet.
Inventory-Led Working Capital Cycle Lengthens
Kiniksa's cash conversion cycle has held in the 52-68 day range, with DIO at 62 days in 2026Q3 dwarfing DSO of 9 days and DPO of 6 days, according to reported balance sheets, indicating working capital intensity is concentrated almost entirely in biologic inventory holdings.
The 9-day DSO confirms a highly efficient specialty-distributor collection structure typical of high-touch orphan drug commercialization, where wholesalers pay quickly against predictable demand — this supports the earnings-quality observation that operating cash flow has consistently exceeded net income. However, the 62-day inventory position and near-zero DPO (Kiniksa pays suppliers essentially on receipt) mean the company funds almost the entire cycle from its own cash, which is comfortable at current scale but would tighten if channel inventory built ahead of a launch or payer disruption slowed sell-through. The CCC trending down from 68 days in 2024Q2 to 65 days alongside rising asset turnover (0.20 to 0.30) points to improving, though not exceptional, working capital discipline as the commercial engine scales.
Multiples Price in Platform Transition Premium
Kiniksa trades at a TTM P/E of 118.9 and forward P/E of 65.3, with EV/EBITDA of 84.3x and P/S of 10.0x, implying investors are pricing a multi-asset outcome rather than the current ARCALYST-driven earnings stream alone, based on current market pricing data.
The forward P/E compression from 118.9 to 65.3 reflects expected earnings growth off a small, recently positive base — a denominator effect rather than evidence of a cheap valuation on any absolute measure. At 10.0x sales and a P/FCF of 267.5x, the market is essentially paying for pipeline optionality (KPL-404, vixarelimab milestones) and potential strategic-buyer premium, consistent with the acquisition-target framing noted in the peer context. Given the Regeneron profit share structurally caps gross margin near 55%, the risk-reward at these multiples is asymmetric: any deceleration in ARCALYST new patient starts or KPL-404 differentiation failure could compress multiples materially, since there is little margin expansion left to support the growth narrative.
Only Profitable Name Commands Peer-Group Premium
Against a peer set of ARDX, PRAX, RCUS, IMVT, and CABA — all carrying negative ROE and mostly negative net margins — Kiniksa's 16.6% net margin and 0.01 D/E distinguish it fundamentally, yet its P/B of 12.4x far exceeds the peer range of 1.3-6.9x, per available peer data.
The profitability gap versus peers appears structural rather than temporary, as Kiniksa has already achieved commercial self-funding while comparables remain dependent on capital markets, meaning the divergence is unlikely to close through peer improvement alone. However, the P/B premium of roughly 2x the highest peer multiple (IMVT at 6.18x) is not obviously justified by ROE alone — at 6.9%, Kiniksa's ROE is positive but not yet at levels that typically command such a book-value multiple, so the premium must be attributed to growth expectations and pipeline optionality rather than current return generation. Sobi and Argenx, referenced as the true operational and valuation peers respectively, are not included in this data set, so this comparison should be treated as directional rather than conclusive for relative-value positioning.
P/E Misapplied to a Recently Profitable Single-Asset Biotech
The 118.9x trailing P/E is the ratio most commonly misapplied here, since it rests on a profit base that only turned positive in 2025Q1 and is further distorted by accelerating SBC and prior-year loss denominators, per Kiniksa's quarterly filings, making it analytically unreliable for this business model.
What the P/E obscures is the difference between accounting profitability achieved during a commercial ramp and durable earning power constrained by the Regeneron profit share — investors should instead anchor on EV/Sales or risk-adjusted pipeline value, since the gross margin ceiling means incremental revenue will not translate to margin expansion the way a normalized P/E assumes. A second commonly misapplied metric is the 3.91x current ratio, which reads as fortress liquidity but reflects an asset-light model with near-zero fixed capital and cash that, based on reported balance sheets, has already drawn down from $190.0M to $81.7M over two quarters; the more informative signal is the absence of any debt service requirement (D/E of 0.01), which removes refinancing risk independent of the headline ratio.